Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.
Hosted on MSN46m
Navigating Care Through Every Phase of Metastatic Breast CancerMedically reviewed by Forest Miller, OTR/L When you are managing metastatic breast cancer, planning for the future is both ...
The Rolling Stones on Thursday led tributes to Sixties music icon Marianne Faithfull, adding she would be forever remembered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback